Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 4

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 4
---
 in this Annual Report
on Form 10-K (this “Form 10-K”) may constitute forward-looking statements for purposes of the Securities Act of
1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to
be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements.
The words “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would”and
similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially from the results
anticipated in these forward-looking statements due to a variety of factors, including, without limitation, those discussed under the
caption “Risk Factors,” set forth in Part I, Item 1A of this Form 10-K. Such forward-looking statements include, but are not
limited to, statements about our:

| ● | expected losses; |

| ● | expectations for increases or decreases in expenses; |

| ● | the substantial doubt expressed about our ability to continue as a going concern; |

​

| ● | expectations for future capital requirements; |

​

| ● | expectations for generating revenue or becoming profitable on a sustained basis; |

​

| ● | expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidates or any other products we may acquire or in-license; |

| ● | use of clinical research centers and other contractors; |

| ● | expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities; |

​

| ● | expectations or ability to enter into marketing and other partnership agreements; |

| ● | expectations or ability to enter into product acquisition and in-licensing transactions; |

| ● | expectations or ability to build our own commercial infrastructure to manufacture, market and sell our product candidates, if approved; |

| ● | expectations for the acceptance of our product candidates, if approved, by doctors, patients or payors; |

| ● | ability to compete against other companies and research institutions; |

| ● | ability